Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation
In conclusion, prolonged AI and/or LS infusions in HF are safe and beneficial even in small infants, allowing stabilization and reasonable social and family life out of the hospital. It may provi de precious time for heart transplantation or myocardial remodeling, improvement, and possible discontinuation even after long periods of support.
ConclusionsPatients with CMS were more likely to present with increased comorbidities. Patients with CMS undergoing CABG were at risk for worse short ‐term secondary postoperative outcomes and reduced long‐term survival. The data supports the need for further investigation for risk reduction surrounding operative revascularization.
AbstractThe first successful human heart transplantation was reported on 3 December 1967, by Christiaan Barnard in South Africa. Since then this life ‐saving procedure has been performed in over 120 000 patients. A limitation to the performance of this procedure is the availability of donor hearts with as many as 20% of patients dying before a donor's heart is available for transplant. Today, hearts for transplantation are procured from indiv iduals experiencing donation after brain death (DBD). Interestingly, this, however, was not always the case as the first heart transplants occurred after circulatory dea...
ConclusionsTransplanting kidneys from HCV-viremic donors into HCV-uninfected recipients increased quality-adjusted life expectancy and reduced costs compared with a strategy of transplanting kidneys from HCV-unexposed donors.
Conclusion: the moments of discussion favored by this study served as learning to continue the future implementation of the strategies pointed out by the group and thus increasingly improve the care provided to patients with heart disease and their families.RESUMEN Objetivo: identificar, junto con el equipo de enfermer ía, estrategias para promover la seguridad del paciente en tratamiento con warfarina. Método: investigación exploratoria y descriptiva con enfoque cualitativo, realizada en las unidades de internación clínica/quirúrgica de un hospital público de referencia en ...
Condition: Coronary Artery Disease Interventions: Diagnostic Test: CT angiography; Diagnostic Test: Invasive coronary angiography Sponsors: Johns Hopkins University; Canon Medical Systems Recruiting
Conditions: Sleep; Multiple Myeloma Interventions: Behavioral: Mindfulness Awareness Practices for Insomnia; Behavioral: Sleep Health Information Sponsor: Medical College of Wisconsin Not yet recruiting
Condition: Vitiligo Interventions: Procedure: Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVA); Device: RECELL 1:5 and Ultraviolet Lamp (UVA); Device: RECELL 1:10 and Ultraviolet Lamp (UVA); Device: RECELL 1:20 and Ultraviolet Lamp (UVA) Sponsor: Avita Medical Not yet recruiting
Condition: Chronic Thromboembolic Pulmonary Hypertension Interventions: Drug: Macitentan; Drug: Placebo Sponsor: Actelion Not yet recruiting
Condition: 2019-nCoV Intervention: Sponsor: Chongqing Medical University Recruiting
The Life Extension Advocacy Foundation volunteers here interview Hanadie Yousef of Juvena Therapeutics. Her team is mining the secretions of pluripotent stem cells to find factors that can improve regeneration and stem cell activity in older individuals. Juvena represents one small slice of a broad trend in the regenerative medicine community, many teams building on the past decades of work on stem cell transplantation by seeking to understand and manipulate the cell signaling thought to produce benefits in patients undergoing these first generation therapies. In near all such stem cell therapies, the transplanted cells di...